Nebivolol Azevedos (Nebivolol Hydrochloride)

Nebivolol, the active ingredient in Nebivolol Azevedos, is a beta blocker presented as an oral formulation for oral use. It treats elevated blood pressure and supports heart function in patients with heart failure. GNH USA supplies Nebivolol Azevedos as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Nebivolol Azevedos is a selective β1‑adrenergic antagonist used in cardiovascular disease management.

Hypertension: lowers blood pressure by reducing cardiac output and promoting vasodilation. Heart failure: improves left ventricular ejection fraction and reduces symptoms of chronic heart failure.

Nebivolol may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Headache: mild to moderate pain in the head. - Dizziness: sensation of light‑headedness, especially on standing. - Fatigue: unusual tiredness or lack of energy. - Bradycardia: slower than normal heart rate. - Nausea: feeling of stomach upset. - Peripheral edema: mild swelling of the lower limbs.

Serious or Rare Side Effects: - Severe bradycardia: markedly low heart rate requiring medical attention. - Hypotension: dangerously low blood pressure. - Bronchospasm: narrowing of airways, especially in patients with asthma. - Allergic reactions: rash, itching, or swelling. - Hepatic dysfunction: abnormal liver enzyme elevations. - Cardiac conduction disorders: heart block or arrhythmias.

Before prescribing Nebivolol Azevedos, clinicians should consider several safety measures.

Monitor blood pressure: ensure adequate control without excessive hypotension. Assess cardiac function: evaluate heart rate and rhythm regularly. Use caution in asthma/COPD: β‑blockade may exacerbate bronchospasm. Adjust in renal/hepatic impairment: dose may need modification. Avoid abrupt discontinuation: taper to prevent rebound hypertension. Store at room temperature: keep in the original pack, protect from moisture.

Nebivolol can interact with other medicines, requiring careful management.

Major Interactions (Avoid): - Other beta blockers: additive cardiac depression. - Calcium channel blockers (verapamil, diltiazem): increased bradycardia risk. - Strong CYP2D6 inhibitors (paroxetine, fluoxetine): elevated nebivolol levels. - Insulin or oral hypoglycemics: enhanced hypoglycemia. - Clonidine: additive hypotensive effect.

Moderate Interactions (Monitor Closely): - NSAIDs: may blunt antihypertensive effect. - Diuretics: risk of electrolyte imbalance. - Other antihypertensives: cumulative blood pressure lowering. - Antiarrhythmic agents: potential conduction disturbances. - Digoxin: monitor for bradycardia.